Remdesivir (RDV) and Hydroxychloroquine (HCQ) have become the most politicized drugs in the world amid Coronavirus. Since HCQ was being strongly recommended by President Trump and many other politicians, the big pharmaceutical companies and their loonies in government regulatory bodies started downplaying its impact.
Instead of cheap and effective HCQ, the big pharmaceutical companies came up with RDV, a drug manufactured Gilead Sciences- an American biopharmaceutical multinational. RDV is priced many times more than HCQ. The big pharmaceutical also maligned HCQ by producing studies which argued that death rate increases with the use of the cheap anti-malarial drug. Now a study has revealed that the risks associated with RDV are being played down by many researchers while the risk with HCQ is being highlighted.
As per an analysis by Dr Sumit Dang from the University of Kentucky, US, Dr Amit Dang, founder and CEO of the Telangana-based MarksMan Healthcare, and Dr Vallish B.N., senior consultant at MarksMan Healthcare, published in peer-reviewed journal Indian Journal of Medical Ethics (IJME), the researchers are playing down the risks associated with RDV.
This might be driven by “political affiliation, profiteering, and other conflicts of interest cannot be ruled out at this stage”, argued researchers in an article titled “Hydroxychloroquine and Remdesivir (RDV) in COVID-19: A critical analysis of recent events”, published in India’s only journal in bioethics and medical ethics.
“Criticism of HCQ has been focused on safety (increased risk of adverse events and arrhythmias), followed by efficacy (lack of clinical or mortality benefit). However, there has been no acknowledgement of the high dose of HCQ given [during trials] when compared to the lower dose recommended by the Indian Council of Medical Research (ICMR),” wrote the researchers.
“On the other hand, the lack of mortality benefit with RDV is being downplayed, and attempts to highlight a lack of new safety risks, despite observations to the contrary, are repeatedly made. It appears as if HCQ is being more closely scrutinised when compared to the lighter treatment given to RDV,” they added.
The fight between HCQ, a cheap anti-malarial drug primarily produced in India, and Remdesivir, a drug promoted by big pharmaceutical companies which are being supported by their loonies in government authorities and Western medical journals, has been very interesting.
Countries like India and Israel, which are relying primarily on HCQ for treatment of Corona virus-infected individuals, has been extremely low while the Western countries which are treating the disease with RDV, have surprisingly high death rates- in some countries hundreds of times more than India.
On June 5, The Lancet, the premier British medical journal with impact factor of 59, was forced to retract a study, which claimed the use of Hydroxychloroquine (HCQ) to treat the Covid-19 increased the mortality rate among patients, and publish a correction (read public apology).
Today, three of the authors have retracted "Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis" Read the Retraction notice and statement from The Lancet https://t.co/pPNCJ3nO8n pic.twitter.com/pB0FBj6EXr
— The Lancet (@TheLancet) June 4, 2020
Read the timeline of TFI on whole HCQ saga, which was downplayed by West because it is primarily produced in India, and big pharmaceutical companies in West would not have benefitted if the cheap anti-malarial drug would have been used for treatment.
We, at TFI, do not usually do chest-thumping, but we are proud to be vindicated on every story reported on Hydroxychloroquine. The whole HCQ saga also exposes the nexus of big pharmaceutical companies, financial media houses, and most reputed medical journals. Also, the moral of the story is that unnecessary politicization of science by left or right, could lead to massive damage to human beings.